BRAF and cancer: Continuous drug-related toxicity is also a risk, and the intermittent targeting of mutant BRAF can lead to the development of new drug-resistant tumors.418,421–423 As Vemurafenib-resistant cancer cells are reliant on the presence of the drug, withdrawal of drug treatment could be sufficient to induce tumor regression.418,422 Although the development of resistance to multiple inhibitors targeting the MAPK pathway remains to be addressed, this drug combination approach improves patient outcomes.424,425